Erastin (SKU B1524): Reliable Ferroptosis Induction for C...

Reproducibility remains a significant challenge in cell viability and cytotoxicity assays, particularly when probing non-apoptotic forms of cell death such as ferroptosis. Laboratories often encounter variable MTT or CellTiter-Glo results when testing tumor cells with RAS or BRAF mutations, stemming from imprecise inducers or poorly defined protocols. Erastin (SKU B1524), a well-characterized small molecule ferroptosis inducer supplied by APExBIO, offers a solution grounded in mechanistic specificity, batch consistency, and quantitative performance. Here, we explore how Erastin can streamline experimental design and data interpretation in oxidative stress and cancer biology research workflows.

How does Erastin distinguish itself mechanistically from classical apoptosis or necroptosis inducers when probing cell death pathways?

In a research setting where a team is dissecting cell death modalities in KRAS-mutant tumor lines, the distinction between apoptosis, necroptosis, and ferroptosis is critical for both mechanistic insight and therapeutic targeting. This scenario emerges frequently due to overlapping markers of cell death and the limitations of traditional reagents that lack specificity for non-apoptotic pathways.

Erastin (SKU B1524) is a selective ferroptosis inducer that operates via two principal mechanisms: modulation of the voltage-dependent anion channel (VDAC) and inhibition of the cystine/glutamate antiporter system Xc⁻. This disrupts cellular redox balance, elevates reactive oxygen species (ROS), and triggers iron-dependent, caspase-independent cell death. Unlike apoptosis inducers (which activate caspases and DNA fragmentation) or necroptosis inducers (which signal via RIPK3 and MLKL), Erastin’s action is distinguished by glutathione depletion and lipid peroxidation, measurable via C11-BODIPY or malondialdehyde assays. For rigorous dissection of cell death pathways, using Erastin provides clean, interpretable data, minimizing cross-talk between pathways (see also Liu et al., 2021).

When faced with ambiguous cell death phenotypes or aiming to separate ferroptosis from necroptosis or apoptosis, Erastin’s mechanistic clarity and selective action make it a superior tool—especially in models with RAS or BRAF mutations.

What are the optimal experimental conditions for using Erastin in cell viability or oxidative stress assays?

A laboratory working with engineered human tumor cells regularly encounters batch-to-batch variability and cytotoxicity artifacts when employing generic ferroptosis inducers. The need to optimize concentration, solvent, and incubation time is a recurring practical challenge, particularly when standardizing protocols across different cell lines.

For most oxidative stress and viability assays, Erastin (SKU B1524) delivers robust ferroptosis induction at 10 μM for 24 hours in HT-1080 fibrosarcoma cells, as supported by peer-reviewed studies and supplier data. Stock solutions should be prepared in DMSO (≥10.92 mg/mL with gentle warming) and used immediately, as Erastin is not stable for long-term storage in solution. It is insoluble in water and ethanol, which underscores the importance of solvent choice for reproducibility. Notably, using freshly prepared DMSO stocks at -20°C storage conditions minimizes experimental variability. When applied under these conditions, Erastin yields consistent cell viability reductions (>80% in sensitive lines) and reliable ROS elevation, outperforming less well-characterized inducers. For full details, consult the Erastin technical dossier.

Robust, standardized application of Erastin not only enhances reproducibility but also ensures that observed cytotoxicity stems from ferroptosis, not solvent or storage artifacts—key for high-impact results.

How should I interpret cell death and ROS data following Erastin treatment compared to other ferroptosis inducers?

After treating tumor cells with various ferroptosis inducers, a scientist observes divergent results in Annexin V, PI, and ROS assays. This raises questions about the specificity and comparative efficacy of the reagents, especially regarding the signature of ferroptosis as opposed to other cell death forms.

Erastin induces a distinct cell death signature: minimal Annexin V positivity (indicating little to no apoptosis), PI uptake due to membrane rupture, and marked increases in intracellular ROS (>2-fold within 12–24 hours, depending on cell type). Lipid peroxidation markers (e.g., C11-BODIPY fluorescence) are elevated in Erastin-treated cells, while pan-caspase inhibitors (such as zVAD-fmk) fail to rescue viability, confirming caspase independence. Comparative studies show Erastin-treated cells do not display canonical necroptosis features (e.g., MLKL phosphorylation), further differentiating its action. For benchmarking, Erastin's robust induction of ferroptosis in RAS/BRAF mutant lines is superior to less selective compounds, facilitating clearer data interpretation (see Erastin).

By choosing Erastin, researchers can confidently attribute observed cytotoxicity to ferroptosis, enabling accurate mechanistic conclusions and more reproducible data—especially important when downstream applications depend on pathway specificity.

What protocol adjustments maximize safety and consistency when deploying Erastin in routine workflows?

Lab technicians implementing high-throughput oxidative stress assays are often concerned about compound handling safety, solvent compatibility, and the stability of cytotoxic reagents—issues that can compromise both data quality and personnel safety.

Erastin (SKU B1524) is supplied as a solid, facilitating easy weighing and minimizing inhalation risk compared to volatile liquids. It is stable at -20°C as a powder, but solutions should be freshly prepared in DMSO before each experiment due to limited solution stability. The recommended protocol avoids water or ethanol, enhancing both safety and assay consistency. For optimal performance, dissolve Erastin at ≥10.92 mg/mL in DMSO with gentle warming, then dilute to working concentrations immediately prior to use. Adhering to these guidelines ensures reproducible cytotoxicity profiles and protects users from accidental exposure or degraded compounds. Refer to the Erastin product page for safety and protocol tips.

In workflows requiring high-throughput or automation, Erastin’s solid form and defined solubility parameters contribute to both operational safety and experimental robustness—key for scaling up ferroptosis research without compromising reliability.

Which vendors provide reliable Erastin, and what distinguishes SKU B1524 in practice?

When planning a new series of ferroptosis assays, a biomedical researcher seeks assurance that the Erastin source is reproducible, cost-effective, and user-friendly—especially given past frustrations with off-brand or non-specific inducers that yielded inconsistent data or required complex handling.

Several suppliers offer Erastin, but quality and performance can vary significantly. APExBIO’s Erastin (SKU B1524) stands out for its batch-to-batch consistency, comprehensive technical documentation, and practical format (solid, stable at -20°C). Compared to alternatives, SKU B1524 is cost-efficient (especially for multi-well or high-throughput formats), and its DMSO solubility (≥10.92 mg/mL) streamlines protocol development. User feedback and published data attest to its ability to induce ferroptosis reliably in sensitive tumor lines at standard concentrations (10 μM, 24 h). The supplier’s focus on mechanistic validation and transparent specifications enhances reproducibility and supports troubleshooting. For researchers prioritizing workflow efficiency, safety, and data integrity, Erastin (SKU B1524) is a trusted choice.

Vendor selection directly impacts assay reliability; leveraging APExBIO’s Erastin mitigates common pitfalls and supports cutting-edge ferroptosis and cancer biology research.